Showing results (571-580 of 2,688) with videos related to

Sort By:
Pageof 269
The Lancet. Infectious Diseases|February 7, 2025
Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trialA Fabrice Somé, Anthony Somé, Emmanuel Sougué, et al.
The Lancet. Infectious Diseases|January 24, 2025
Chronic intestinal spirochaetosis and Giardia lamblia infection mimicking eosinophilic enterocolitisMaria Antonia De Francesco, Luca Paroni, Francesco Lanzarotto, et al.
The Lancet. Infectious Diseases|December 13, 2024
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in childrenHamtandi M Natama, Jo Salkeld, Athanase Somé, et al.
The Lancet. Infectious Diseases|March 1, 2025
Impact of the Global Fund Regional Artemisinin-resistance Initiative on malaria control and elimination in the Greater Mekong subregion of southeast AsiaCaitlin Pley, Harry Gibbs, Prayuth Sudathip, et al.
The Lancet. Infectious Diseases|December 8, 2024
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trialTerry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
The Lancet. Infectious Diseases|December 1, 2024
Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysisAbhinav Sengupta, Animesh Ray, Ashish Datt Upadhyay, et al.
The Lancet. Infectious Diseases|August 23, 2024
Effectiveness of rVSV-ZEBOV vaccination during the 2018-20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative studySophie Meakin, Justus Nsio, Anton Camacho, et al.
The Lancet. Infectious Diseases|November 28, 2024
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trialJaya Goswami, Jose F Cardona, Denise C Hsu, et al.
The Lancet. Infectious Diseases|November 18, 2024
Expansion of Oropouche virus in non-endemic Brazilian regions: analysis of genomic characterisation and ecological driversTiago Gräf, Edson Delatorre, Caroline do Nascimento Ferreira, et al.
The Lancet. Infectious Diseases|November 11, 2024
Antimicrobial resistance among refugees and asylum seekers: a global systematic review and meta-analysisElizabeth D Hermsen, James Amos, Andy Townsend, et al.
Pageof 269